Suzhou Ribo Life Science Submits Phase II Clinical Trial Application for RBD1119 Injection to Treat Coronary Artery Disease 1
Suzhou Ribo Life Science Announces Phase II Clinical Trial A...
Sign in to continue:
Suzhou Ribo Life Science Announces Phase II Clinical Trial A...
Sinopharm Group Co. Ltd. Announces Domestic Shareholders’ Cl...
Sinopharm Group Co. Ltd. Announces H Shareholders’ Class Mee...
CIG Shanghai Announces HK\$1.97 Billion H Share Placement Un...
Antengene Announces CDE Approval for Pivotal Phase III CLINC...
Beijing Biostar Pharmaceuticals: Utidelone Clinical Data Sel...
CT Vision (International) Holdings Limited Announces Share S...
CA Cultural Technology Group - Major Corporate Update ...
Hengxin Technology Business Update: Participation in Nationa...
Ascentage Pharma Announces Trustee Share Purchase for 2022 R...